Pancragen 20mg
Pancreatic Peptide Bioregulator for Islet and Endocrine Research
Pancragen is a Khavinson tetrapeptide bioregulator targeting pancreatic tissue, normalizing gene expression in islet and exocrine cells to support pancreatic function and metabolic health.
Pancreatic Peptide Bioregulator for Islet and Endocrine Research
Pancreatic tissue-specific peptide bioregulator supporting islet cell gene expression normalization and pancreatic function through epigenetic modulation, relevant for diabetes and metabolic research.
As one of the most studied compounds in the recovery & healing research space, Pancragen has attracted sustained scientific interest across Pancreatic tissue research, Diabetes-related studies, Islet biology. Peer-reviewed evidence indicates that pancreas-specific Khavinson bioregulator, which has positioned Pancragen as a reference standard for researchers exploring pancreatic tissue research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Pancragen Documented Benefits: 1 Documented Mechanisms
Pancreatic Support
Normalizes islet and exocrine pancreatic cell gene expression for endocrine health.
How Pancragen Works: Molecular Mechanism & Pathway
Short peptide with pancreatic tissue specificity modulating epigenetic gene expression in islet and acinar cells.
The 1 primary research pathways identified for Pancragen — Pancreatic Support — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that islet cell gene expression support, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Pancragen's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Pancragen is routinely studied alongside NAD+ and Livagen in recovery & healing-focused compound panels. Researchers investigating pancreatic tissue research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 20mg standard has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Pancragen research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Pancreas-specific Khavinson bioregulator
- Islet cell gene expression support
- 20mg standard
Ideal For
- Pancreatic tissue research
- Diabetes-related studies
- Islet biology
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Pancragen. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Pancreas-specific Khavinson bioregulator
Islet cell gene expression support
20mg standard
Third-Party Verified Every Batch
Each vial of Pancragen is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
